Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
(2021) Leukemia — Vol. 35, n° 7, p. 2119-2124 (2021)
Files
SekeresMALeukemia2021.pdf
Open Access - Adobe PDF
- 1.23 MB
Details
- Authors
Sekeres, Mikkael A 
- Abstract
- (en) TO THE EDITOR : There is a critical unmet need for novel treatments for higher-risk myelodysplastic syndromes (MDS), higher-risk chronic myelomonocytic leukemia (CMML), and low-blast (LB) acute myeloid leukemia (AML). For patients ineligible for stem cell transplant (SCT), standard therapy with hypomethylating agents, such as azacitidine and decitabine, is not curative, with most patients relapsing within 2 years. [...]
- Affiliations
Citations
Sekeres, M. A., Watts, J., Radinoff, A., Sangerman, M. A., Cerrano, M., Lopez, P. F., Zeidner, J. F., Campelo, M. D., Graux, C., Liesveld, J., Selleslag, D., Tzvetkov, N., Fram, R. J., Zhao, D., Bell, J., Friedlander, S., Faller, D. V., & Adès, L. (2021). Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML. Leukemia, 35(7), 2119-2124. https://doi.org/10.1038/s41375-021-01125-4 (Original work published 2021)